专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09638700B2 NT-pro ANP and SFlt-1 for the differentiation between circulatory and ischemic events 有权
公开(公告)号：US09638700B2
公开(公告)日：2017-05-02
申请号：US13461833
申请日：2012-05-02
申请人： Georg Hess , Dietmar Zdunek , Andrea Horsch
发明人： Georg Hess , Dietmar Zdunek , Andrea Horsch
IPC分类号： G01N33/53 , G01N33/68
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2333/71 , G01N2800/32 , G01N2800/347
摘要： The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.

2. 发明申请

US20110229907A1 USE OF CARDIAC HORMONES TO ASSESS RISK OF CARDIOVASCULAR COMPLICATION FROM VOLUME OVERLOAD 审中-公开
标题翻译：使用心脏瓣膜来评估体积过载的心脏血管紧张素的风险
公开(公告)号：US20110229907A1
公开(公告)日：2011-09-22
申请号：US13118938
申请日：2011-05-31
申请人： Georg Hess , Andrea Horsch
发明人： Georg Hess , Andrea Horsch
IPC分类号： G01N33/53
CPC分类号： C07K14/58 , C07K14/57509 , G01N33/58 , G01N33/6893 , G01N33/74 , G01N2333/58 , G01N2800/32 , G01N2800/324
摘要： The disclosure relates to the use of cardiac hormones, particularly natriuretic peptides, for assessment of risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of intravasal volume overload. In particular, the disclosure relates to a method for diagnosing the risk of a patient whose intravasal volume is increased or will be increased of suffering from a cardiovascular complication as a consequence of the increase of intravasal volume, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone such as NT-proBNP.
摘要翻译：本公开内容涉及心脏荷尔蒙，特别是利钠肽用于评估由于血管内体积过量而引起的心血管并发症，特别是心脏病或急性冠状动脉综合征的风险。特别地，本公开涉及一种用于诊断患者的风险的方法，所述患者的胸腔积量增加或由于胸腔内体积的增加而引起的心血管并发症的增加，包括以下步骤：（a）体液或组织样品，以及（b）优选在体外测量心脏激素水平如NT-proBNP。

3. 发明申请

US20110207629A1 PREDICTING CARDIOVASCULAR EVENTS AND RENAL FAILURE IN TYPE 1 DIABETICS 审中-公开
标题翻译：预防1型糖尿病的心血管事件和肾功能衰竭
公开(公告)号：US20110207629A1
公开(公告)日：2011-08-25
申请号：US13102093
申请日：2011-05-06
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： C40B30/04 , C40B60/12 , C40B40/04
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2333/78 , G01N2800/32
摘要： The present invention relates to a method for predicting or assessing the risk of a type 1 diabetes patient to suffer from a cardiovascular event and/or terminal renal failure and/or death. The method is based on the determination of adiponectin and optionally a natriuretic peptide in a sample of a subject suffering from type 1 diabetes. Moreover, the present invention pertains to a method for predicting the risk of a cardiovascular event, mortality or terminal renal failure for a subject suffering from type 1 diabetes based on the determination of adiponectin and optionally a natriuretic peptide in a sample of the subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.
摘要翻译：本发明涉及一种用于预测或评估1型糖尿病患者患有心血管事件和/或终末性肾衰竭和/或死亡的风险的方法。该方法基于在患有1型糖尿病的受试者样品中脂联素和任选的利尿钠肽的测定。此外，本发明涉及一种用于根据受试者样品中脂联素和任选的利尿钠肽的测定来预测患有1型糖尿病的受试者的心血管事件，死亡率或终末期肾衰竭风险的方法。本发明还包括用于实施上述方法的装置和试剂盒。

4. 发明授权

US08003396B2 NT-proBNP/troponin ratio for assessing myocardial dysfunction 失效
标题翻译： NT-proBNP /肌钙蛋白比值用于评估心肌功能障碍
公开(公告)号：US08003396B2
公开(公告)日：2011-08-23
申请号：US12748879
申请日：2010-03-29
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/00
CPC分类号： G01N33/68 , G01N33/5302 , G01N33/6887 , G01N33/6893 , G01N2333/58 , G01N2800/325
摘要： The present invention relates to a method of diagnosing if a subject which has suffered from an acute myocardial infarction is also suffering from a pre-existing myocardial dysfunction, the method comprising a) determining the amount of a natriuretic peptide in a sample of the subject; b) determining the amount of a cardiac troponin in a sample of the subject; c) calculating the ratio (natriuretic peptide/cardiac troponin); and d) diagnosing if the elevated natriuretic peptide level is related to a preexisting myocardial dysfunction or if the elevated level is caused by the acute myocardial infarction, based on the ratio calculated in step c). The method allows determining whether the individual has suffered from a myocardial dysfunction, in particular heart failure, before the myocardial infarction has occurred.
摘要翻译：本发明涉及一种诊断是否患有急性心肌梗死的受试者也患有预先存在的心肌功能障碍的方法，所述方法包括：a）确定受试者样品中利尿钠肽的量; b）确定受试者样品中心肌肌钙蛋白的量; c）计算比例（利钠肽/心肌肌钙蛋白）; 以及d）基于在步骤c）中计算的比率来诊断升高的利尿钠肽水平是否与预先存在的心肌功能障碍相关，或者如果升高的水平是由急性心肌梗死引起的。该方法允许在发生心肌梗死之前确定个体是否患有心肌功能障碍，特别是心力衰竭。

5. 发明申请

US20110113865A1 USING CARDIAC TROPONIN FOR MONITORING ANTI-ANGIOGENESIS THERAPY 审中-公开
标题翻译：使用CARDIAC TROPONIN监测抗血栓形成治疗
公开(公告)号：US20110113865A1
公开(公告)日：2011-05-19
申请号：US13010242
申请日：2011-01-20
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/48
CPC分类号： G01N33/6887 , G01N2333/4712 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to a method for monitoring subjects being on anti-angiogenesis therapy based on determining the amount of a cardiac troponin in a first and second sample of a subject and comparing the amount in the first sample with the second sample. Thereby, it can be assessed whether a subject is susceptible to a continuation of the therapy or not. Moreover, the present invention relates to a method for predicting the risk of a cardiovascular event as a consequence of anti-angiogenesis therapy. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种基于测定受试者的第一和第二样本中的心肌肌钙蛋白的量来监测受试者的抗血管生成治疗的方法，并将第一样品中的量与第二样品进行比较。因此，可以评估受试者是否容易继续进行治疗。此外，本发明涉及一种用于预测作为抗血管生成治疗的结果的心血管事件风险的方法。本发明还包括适用于实施本发明方法的试剂盒和装置。

6. 发明申请

US20110111527A1 MULTIMARKER PANEL FOR DIFFERENTIATION OF DILATED CARDIOMYOPATHY AND AS A BASIS FOR DIFFERENTIAL THERAPY 审中-公开
标题翻译：用于差异性心脏病的差异的多重面板和作为差异治疗的基础
公开(公告)号：US20110111527A1
公开(公告)日：2011-05-12
申请号：US12944874
申请日：2010-11-12
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/325
摘要： The present invention relates to a method for diagnosing if a subject suffering from dilated cardiomyopathy is suffering from ischemic or non-ischemic dilated cardiomyopathy. Further, it relates to a method of determining which medication is to be applied in a subject suffering form after dilated cardiomyopathy. The method includes the steps of determining amounts of troponin, GDF-15, and an angiogenic markers selected from the group of PlGF, endoglin, and sFlt-1 in a sample from the subject and comparing the amounts determined With reference amounts. In one embodiment, the method of the invention further comprises also measuring an amount of a natriuretic peptide.
摘要翻译：本发明涉及一种用于诊断患有扩张型心肌病的受试者是否患有缺血性或非缺血性扩张性心肌病的方法。此外，本发明涉及一种确定哪种药物应用于扩张性心肌病后受试者的方法。该方法包括确定来自受试者的样品中肌钙蛋白，GDF-15和选自PlGF，内皮糖蛋白和sFlt-1组的血管生成标志物的量的步骤，并比较用参考量确定的量。在一个实施方案中，本发明的方法还包括测量利尿钠肽的量。

7. 发明申请

US20110082349A1 MEANS AND METHODS FOR DETERMINING THE ARTERIOSCLEROTIC STENOSIS USING INFLAMMATORY BIOMARKERS 审中-公开
标题翻译：使用炎症生物标志物确定动脉粥样硬化性狭窄的手段和方法
公开(公告)号：US20110082349A1
公开(公告)日：2011-04-07
申请号：US12966262
申请日：2010-12-13
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： A61B5/00 , G01N33/68 , G01N33/92
CPC分类号： G01N33/6893 , C07K14/4737 , G01N33/92 , G01N2333/4737 , G01N2800/323
摘要： The present invention relates to a method for diagnosing the degree of arteriosclerotic stenosis in a subject including determining the amount of CRP or LPa in a sample of the subject and comparing the determined amount to a reference whereby the degree of arteriosclerotic stenosis is determined. The present invention also contemplates a method for identifying a subject in need of prevention or therapy of arteriosclerosis. Further, devices and kits are encompassed for carrying out the methods.
摘要翻译：本发明涉及一种用于诊断受试者的动脉硬化性狭窄程度的方法，包括确定受试者样品中的CRP或LPa的量，并将测定的量与参考相比较，从而确定动脉硬化性狭窄的程度。本发明还考虑了用于鉴定需要预防或治疗动脉硬化的受试者的方法。此外，包括用于执行方法的装置和套件。

8. 发明申请

US20110072892A1 H-FABP AS A MARKER FOR MYOCARDIAL HIBERNATION 审中-公开
标题翻译： H-FABP作为心脏起搏标记
公开(公告)号：US20110072892A1
公开(公告)日：2011-03-31
申请号：US12963122
申请日：2010-12-08
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N1/10
CPC分类号： G01N33/6887 , G01N33/92 , G01N2800/324
摘要： The present invention relates to the use of H-FABP as a marker for myocardial hibernation. Also envisaged by the present invention is the use of H-FABP and a cardiac troponin for differentiating between myocardial necrosis and myocardial hibernation. The present invention also relates to a method for diagnosing myocardial hibernation in a subject based on determining the amount of heart fatty acid binding protein (H-FABP) in a sample of the subject and comparing the thus determined amount to a suitable reference amount. The method further, preferably, furthers comprises comparing the amount of a cardiac troponin in the sample, and comparing the, thus, determined amount to a reference for the cardiac troponin.
摘要翻译：本发明涉及H-FABP作为心肌冬眠标志物的用途。本发明还设想使用H-FABP和心肌肌钙蛋白来分化心肌坏死和心肌冬眠。本发明还涉及一种基于确定受试者样品中心脏脂肪酸结合蛋白（H-FABP）的量并将如此确定的量与适当参考量进行比较的方法来诊断受试者的心肌冬眠。该方法还优选进一步包括比较样品中心肌肌钙蛋白的量，并将因此确定的量与心肌肌钙蛋白的参考值进行比较。

9. 发明申请

US20110059539A1 L-FABP, NATRIURETIC PEPTIDES, AND CARDIAC TROPONINS IN SUBJECTS IN NEED OF CARDIAC THERAPY 有权
标题翻译： L-FABP，NATRIURETIC PEPTIDES和CARDIAC TROPONINS需要治疗心脏病
公开(公告)号：US20110059539A1
公开(公告)日：2011-03-10
申请号：US12944785
申请日：2010-11-12
申请人： Georg Hess , Andrea Horsch , Dietmar Zdunek
发明人： Georg Hess , Andrea Horsch , Dietmar Zdunek
IPC分类号： G01N33/53 , B01L3/00
CPC分类号： G01N33/6893 , G01N2333/4712 , G01N2333/58 , G01N2800/325 , G01N2800/347 , G01N2800/52 , Y10T436/143333
摘要： Disclosed is a method for identifying a subject being susceptible to a cardiac therapy, comprising (a) determining the amounts of liver fatty acid binding protein, and at least one further polypeptide from the group of a cardiac troponin and a natriuretic peptide in at least one sample of a subject suffering from heart failure, (b) comparing the thus determined amounts to suitable reference amounts, and (c) identifying a subject being susceptible to a cardiac therapy. Also described is a device and a kit adapted to carry out the method of the present invention. Also described is the use of liver fatty acid binding protein and at least one further polypeptide from the group of a cardiac troponin and a natriuretic peptide for identifying a subject being susceptible to a cardiac therapy.
摘要翻译：公开了用于鉴定对心脏治疗敏感的受试者的方法，其包括（a）在至少一种中测定肝脏脂肪酸结合蛋白的量和来自心肌肌钙蛋白和利尿钠肽组的至少一种其它多肽患有心力衰竭的受试者的样本，（b）将由此确定的量与合适的参考量进行比较，和（c）鉴定易受心脏病治疗的受试者。还描述了适于实现本发明的方法的装置和套件。还描述了使用肝脏脂肪酸结合蛋白和来自心肌肌钙蛋白和利钠肽的至少一种其它多肽来鉴定对心脏治疗敏感的受试者。

10. 发明授权

US07892844B2 Differentiation of cardiac and pulmonary causes of acute shortness of breath 失效
标题翻译：心脏和肺部急性呼吸短促的原因分化
公开(公告)号：US07892844B2
公开(公告)日：2011-02-22
申请号：US11780560
申请日：2007-07-20
申请人： Georg Hess , Andrea Horsch
发明人： Georg Hess , Andrea Horsch
IPC分类号： G01N33/49 , G01N33/00
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2333/785 , G01N2800/12 , G01N2800/32
摘要： The present invention relates to a method for differentiating in a subject suffering from acute shortness of breath (dyspnea) between (i) a pulmonary disease, (ii) a cardiovascular complication, (iii) a cardiovascular complication accompanied by a pulmonary disease or (iv) acute dyspnea without cardiovascular or pulmonary causes comprising the steps of determining the amount of pulmonary surfactant protein B (SP-B) in a sample of a subject, determining the amount of N-terminal pro-brain natriuretic peptide (NT-proBNP) in a sample of the subject, and differentiating between (i) a pulmonary disease, (ii) a cardiovascular complication, (iii) a cardiovascular complication accompanied by a pulmonary disease or (iv) acute dyspnea without cardiovascular or pulmonary causes by comparing the determined amounts with reference amounts.
摘要翻译：本发明涉及一种在（i）肺部疾病，（ii）心血管并发症，（iii）伴有肺部疾病的心血管并发症或（iv）患者之间患有急性呼吸困难（呼吸困难））没有心血管或肺部原因的急性呼吸困难，包括确定受试者样品中肺表面活性蛋白B（SP-B）的量的步骤，确定受试者的N末端脑钠肽（NT-proBNP）的量（i）肺部疾病，（ii）心血管并发症，（iii）伴有肺部疾病的心血管并发症或（iv）无心血管或肺部原因的急性呼吸困难，通过比较确定的量具有参考量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式